Benzylisoquinolinium, competitive neuromuscular blocker. Prepn: J. B. Stenlake et al., DE 2655883; eidem, US 4179507 (1977, 1979 both to Burroughs Wellcome). Pharmacology: R. Hughes, D. J. Chapple, Br. J. Anaesth. 53, 31 (1981) DOI PubMed. Clinical pharmacology: S. J. Basta et al., Anesth. Analg. 61, 723 (1982) PubMed. Neuromuscular effects in man: R. L. Katz et al., ibid. 730 PubMed. Metabolic studies: E. A. Neill, D. J. Chapple, Xenobiotica 12, 203 (1982) DOI PubMed. Pharmacokinetics: S. Ward et al., Br. J. Anaesth. 55, 113 (1983) DOI PubMed. Use during halothane anesthesia in humans: J. A. Stirt et al., Anesth. Analg. 62, 207 (1983) PubMed. Symposium on pharmacology, metabolism, and clinical studies: Br. J. Anaesth. 55, Suppl. 1, 1S-139S (1983); on pharmacokinetics and clinical experience: ibid. 58, Suppl. 1, 1S-113S (1986).
Prepn: D. A. Hill, G. L. Turner, WO 9200965 (1992 to Wellcome Found.). Clinical pharmacology: C. A. Lien et al., Anesthesiology 82, 1131 (1995) DOI PubMed; M. R. Belmont et al., ibid. 1139 DOI PubMed.
Neuromuscular blocking agent.
Neuromuscular Blocking Agent; Nondepolarizing Agents